Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

Last 30 days: 128 accesses
Last 365 days: 1715 accesses
All time: 5930 accesses

Feng Xie^*, Gord Blackhouse, Nazila Assasi, Kathryn Gaebel, Diana Robertson and Ron Goeree

Cost Effectiveness and Resource Allocation 2009, 7:20 doi:10.1186/1478-7547-7-20

Accesses